Ameya D Puranik1, Harshad R Kulkarni, Aviral Singh, Richard P Baum. 1. THERANOSTICS Centre for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert Koch Allee, Bad Berka, 99437, Germany.
Abstract
PURPOSE: Head and neck paragangliomas (HNPGLs) are rare tumours arising from autonomic nervous system ganglia. Although surgery offers the best chance of complete cure, there is associated morbidity due to the crucial location of these tumours. Radiotherapy arrests tumour growth and provides symptomatic improvement, but has long-term consequences. These tumours express somatostatin receptors (SSTR) and hence peptide receptor radionuclide therapy (PRRT) is now a treatment option. We assessed the molecular, morphological and clinical responses of inoperable HNPGLs to PRRT. METHODS: Nine patients with inoperable HNPGL assessed between June 2006 and June 2014 were included. Four patients had a solitary lesion, four had multifocal involvement and one had distant metastases (bone and lungs). The patients were treated with PRRT using (90)Y/(177)Lu-labelled peptides after positive confirmation of SSTR expression on (68)Ga-DOTATOC PET/CT. All patients received two to four courses of PRRT. Subsequent serial imaging with (68)Ga-DOTATOC PET/CT was carried out every 6 months to assess response to treatment. Clinical (symptomatic) response was also assessed. RESULTS: Based on molecular response (EORTC) criteria, four of the nine patients showed a partial molecular response to treatment seen as significant decreases in SUVmax, accompanied by a reduction in tumour size. Five patients showed stable disease on both molecular and morphological criteria. Six out of nine patients were symptomatic at presentation with manifestations of cranial nerve involvement, bone destruction at the primary site and metastatic bone pain. Molecular responses were correlated with symptomatic improvement in four out of these six patients; while two patients showed small reductions in tumour size and SUVmax. The three asymptomatic patients showed no new lesions or symptomatic worsening. CONCLUSION: PRRT was effective in all patients, with no disease worsening seen, either in the form of neurological symptoms or distant spread. Though these are preliminary results, PRRT shows promise as a good treatment option for HNPGL, and hence study in a larger patient cohort is essential to establish its place in the management algorithm.
PURPOSE: Head and neck paragangliomas (HNPGLs) are rare tumours arising from autonomic nervous system ganglia. Although surgery offers the best chance of complete cure, there is associated morbidity due to the crucial location of these tumours. Radiotherapy arrests tumour growth and provides symptomatic improvement, but has long-term consequences. These tumours express somatostatin receptors (SSTR) and hence peptide receptor radionuclide therapy (PRRT) is now a treatment option. We assessed the molecular, morphological and clinical responses of inoperable HNPGLs to PRRT. METHODS: Nine patients with inoperable HNPGL assessed between June 2006 and June 2014 were included. Four patients had a solitary lesion, four had multifocal involvement and one had distant metastases (bone and lungs). The patients were treated with PRRT using (90)Y/(177)Lu-labelled peptides after positive confirmation of SSTR expression on (68)Ga-DOTATOC PET/CT. All patients received two to four courses of PRRT. Subsequent serial imaging with (68)Ga-DOTATOC PET/CT was carried out every 6 months to assess response to treatment. Clinical (symptomatic) response was also assessed. RESULTS: Based on molecular response (EORTC) criteria, four of the nine patients showed a partial molecular response to treatment seen as significant decreases in SUVmax, accompanied by a reduction in tumour size. Five patients showed stable disease on both molecular and morphological criteria. Six out of nine patients were symptomatic at presentation with manifestations of cranial nerve involvement, bone destruction at the primary site and metastatic bone pain. Molecular responses were correlated with symptomatic improvement in four out of these six patients; while two patients showed small reductions in tumour size and SUVmax. The three asymptomatic patients showed no new lesions or symptomatic worsening. CONCLUSION: PRRT was effective in all patients, with no disease worsening seen, either in the form of neurological symptoms or distant spread. Though these are preliminary results, PRRT shows promise as a good treatment option for HNPGL, and hence study in a larger patient cohort is essential to establish its place in the management algorithm.
Authors: Martijn van Essen; Eric P Krenning; Peter P Kooij; Willem H Bakker; Richard A Feelders; Wouter W de Herder; John G Wolbers; Dik J Kwekkeboom Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: S Lightowlers; S Benedict; S J Jefferies; R Jena; F Harris; K E Burton; N G Burnet Journal: Clin Oncol (R Coll Radiol) Date: 2010-03-04 Impact factor: 4.126
Authors: Jason P Sheehan; Shota Tanaka; Michael J Link; Bruce E Pollock; Douglas Kondziolka; David Mathieu; Christopher Duma; A Byron Young; Anthony M Kaufmann; Heyoung McBride; Peter A Weisskopf; Zhiyuan Xu; Hideyuki Kano; Huai-che Yang; L Dade Lunsford Journal: J Neurosurg Date: 2012-06-08 Impact factor: 5.115
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Dieter Hörsch; Samer Ezziddin; Alexander Haug; Klaus Friedrich Gratz; Simone Dunkelmann; Bernd Joachim Krause; Carl Schümichen; Frank M Bengel; Wolfram H Knapp; Peter Bartenstein; Hans-Jürgen Biersack; Ursula Plöckinger; Sabine Schwartz-Fuchs; R P Baum Journal: Recent Results Cancer Res Date: 2013
Authors: Anthony M Joshua; Shereen Ezzat; Sylvia L Asa; Andrew Evans; Reuben Broom; Marc Freeman; Jennifer J Knox Journal: J Clin Endocrinol Metab Date: 2008-11-11 Impact factor: 5.958
Authors: Manuel Weber; Jochen Schmitz; Ines Maric; Kim Pabst; Lale Umutlu; Martin Walz; Ken Herrmann; Christoph Rischpler; Frank Weber; Walter Jentzen; Sarah Theurer; Thorsten D Poeppel; Nicole Unger; Wolfgang P Fendler Journal: J Nucl Med Date: 2021-09-23 Impact factor: 11.082
Authors: Ingo Janssen; Clara C Chen; Corina M Millo; Alexander Ling; David Taieb; Frank I Lin; Karen T Adams; Katherine I Wolf; Peter Herscovitch; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-21 Impact factor: 9.236
Authors: Ingo Janssen; Clara C Chen; David Taieb; Nicholas J Patronas; Corina M Millo; Karen T Adams; Joan Nambuba; Peter Herscovitch; Samira M Sadowski; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: J Nucl Med Date: 2015-11-12 Impact factor: 10.057
Authors: Abhishek Jha; Mayank Patel; Eva Baker; Melissa K Gonzales; Alexander Ling; Corina Millo; Marianne Knue; Ali Cahid Civelek; Karel Pacak Journal: Nucl Med Mol Imaging Date: 2020-01-22
Authors: Katherine I Wolf; Abhishek Jha; Anouk van Berkel; Damian Wild; Ingo Janssen; Corina M Millo; M J R Janssen; Melissa K Gonzales; Henri J K M Timmers; Karel Pacak Journal: Nucl Med Mol Imaging Date: 2019-02-22
Authors: Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Erik F Zenker; Marc Cartellieri; Michael Bachmann; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Graeme Eisenhofer; Stefan R Bornstein; Jens Pietzsch; Christian G Ziegler Journal: Theranostics Date: 2016-03-10 Impact factor: 11.556